13th Jun 2022 20:36
Spectral MD Holdings Ltd - London and Dallas, Texas-based predictive analytics for wound care - Begins clinical validation study to support the development of its Diabetic Foot Ulcer application for the DeepView Wound Imaging System. The technology combines multi-spectral imaging and artificial intelligence to provide clinicians with an immediate healing assessment for DFU, which enables clinicians to provide a more accurate and timely diagnosis for therapeutic intervention, it explains.
The study will collect data from up to 200 adult subjects across seven potential clinical sites to further develop DeepView's AI algorithm. Patient enrolment for the validation study began this month and is expected to complete in November, it adds.
Current stock price: 34.00 pence
12-month change: down 42% from 59p listing price in June last year
By Arvind Bhunjun; [email protected]
Copyright 2022 Alliance News Limited. All Rights Reserved.
Related Shares:
SMD.L